Trials / Completed
CompletedNCT02251067
Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Phase 2, Two-Part Adaptive Study to Evaluate the Safety and Efficacy of VPI-2690B Injection in Patients With Nephropathy Due to Diabetes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 165 (actual)
- Sponsor
- Vascular Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 21 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether VPI-2690B Injection is effective in the treatment of diabetic nephropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VPI-2690B low dose | Comparison of different doses of study drug |
| DRUG | VPI-2690B medium dose | Comparison of different doses of study drug |
| DRUG | Placebo to match VPI-2690B | |
| DRUG | VPI-2690B high dose | Comparison of different doses of study drug |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2017-03-01
- Completion
- 2017-03-01
- First posted
- 2014-09-26
- Last updated
- 2017-03-28
Locations
34 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT02251067. Inclusion in this directory is not an endorsement.